Biodegradability of the anti-tumour agent ifosfamide and its occurrence in hospital effluents and communal sewage

Water Research

Volumn 31, Issue 11, 1997, Pages 2705-2710

  Kümmerer, Klaus ^a   Steger Hartmann, Thomas ^a,b   Meyer, Michael ^a,c  

^a Inst Environ Med Hosp Epidemiol   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

^c NONE   (Germany)

Author keywords

Anti tumour agent; Biodegradability; Communal sewage; Hospital effluent; Ifosfamide; Sewage treatment; Surface water

Indexed keywords

BIODEGRADATION; DRUG PRODUCTS; EFFLUENT TREATMENT; ENVIRONMENTAL IMPACT; ENVIRONMENTAL PROTECTION; SURFACE WATERS;

ANTI TUMOR AGENTS; COMMUNAL SEWAGE; IFOSFAMIDE;

SEWAGE TREATMENT;

ANTINEOPLASTIC AGENT; CARCINOGEN; IFOSFAMIDE; MUTAGENIC AGENT; TERATOGENIC AGENT;

ARTICLE; BIODEGRADATION; DRUG DEGRADATION; DRUG ELIMINATION; DRUG EXCRETION; ENVIRONMENTAL IMPACT ASSESSMENT; FETOTOXICITY; GAS CHROMATOGRAPHY; HOSPITAL WASTE; MASS SPECTROMETRY; PRIORITY JOURNAL; SEWAGE TREATMENT; WASTE WATER MANAGEMENT;

EID: 0042548456     PISSN: 00431354     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0043-1354(97)00121-8     Document Type: Article

References (21)

1. Allwood M. and Wright P. (1993) The Cytotoxics Handbook. Radcliffe Medical Press. Oxford.
2. ASTA Medica AG (1995) Security data sheet (91/155/EWG) Ifosfamide. 22 April Frankfurt.
3. Boos J., Weslau U., Ritter J., Blaschke G. and Schellong G. (1991) Urinary excretion of the enantiomers of IF and its inactive metabolites in children. Cancer Chemother. Pharmacol. 28, 455-460.
4. DIN (1996) DIN 38 412 Deutsche Einheitsverfahren zur Wasser-, Abwasser-und Schlammuntersuchung (German standard methods for the examination of water waste water and sludge). VCH Verlagsgesellschaft, Weinheim.
5. Ensslin A. S., Stoll Y., Pethran A., Pfaller A., Römmelt H. and Fruhmann G. (1994) Biological monitoring of cyclophosphamide and IF in urine of hospital personnel occupationally exposed to cytostatic drugs. Occup. Environ. Med. 51, 229-233.
6. EU (1995) Direction General III, Assessment of potential risks to the environment posed by medical products for human use (excluding products containing live genetically modified organisms). No. 5504/94 Draft 6, version 4, 5 January, European Union, Brussels.
7. Gilard V., Malet Martine M. C., De Forni, M., Niemeyer U., Ader J. C. and Martino R. (1993) Determination of the urinary excretion of IF and its phosphorylated metabolites by phosphorous-31 nuclear magnetic resonance spectroscopy. Cancer Chemother. Pharmacol. 31, 387-394.
8. Goren M. P. (1991) Determination of urinary 2 and 3-dechloroethylated metabolites of IF by high performance liquid chromatography. J. Chromatogr - Biomed. Appl. 570, 351-360.
9. IARC (1975) Cyclophosphamide, IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals, pp. 135-156. International Agency for Research on Cancer, Lyon.
10. IARC (1981) Cyclophosphamide, IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals, pp. 165-202. International Agency for Research on Cancer, Lyon.
11. Kümmerer K., Steger-Hartmann T., Baranyai A. and Bürhaus I. (1996) Evaluation of the biological degradation of the antineoplastics cyclophosphamide and ifosfamide with the Closed Bottle Test (OECD 301 D). Zbl Hyg. 198, 215-225.
12. Lemmer B. (ed) (1989) Chronopharmacology - Cellular and Biochemical Interactions. Birkhäuser, New York.
13. Martino R., Crasnier F., Chouini Lalanne N., Gilard V., Niemeyer U., De Forni M. and Malet Martino M. C. (1992) A new approach to the study of IF metabolism by the analysis of human body fluids with phosporus-31 nuclear magnetic resonance spectroscopy. J. Pharmacol. Exper. Therap. 260, 1133-1144.
14. Muñoz M., Bonjoch J., Prat J., Pujoö M., Girona V. and de Bolós J. (1996) Degradation kinetics of ifosfamide in aqueous solution. Int. J. Pharmaceut. 139, 249-253.
15. Nyholm N. (1991) The european system of standardized legal tests for assessing the biodegradability of chemicals. Environ. Toxicol. Chem. 11, 1237-1246.
16. OECD (1992) Guidelines for Testing of Chemicals: 302 B Zahn-Wellens Test and 301 A Confirmatory Test, adopted by the Council on 17 July 1992. OECD. Paris.
17. Richardson M. L. and Bowron J. M. (1985) The fate of pharmaceutical chemicals in the aquatic environment. J. Pharm. Pharmacol. 37, 1-12.
18. Sorsa M., Pyy L., Salomaa S., Nylund L. and Yager J. W. (1988) Biological and environmental monitoring of occupational exposure to cyclophosphamide in industry and hospitals. Mut. Res. 204, 465-479.
19. Stan H.-J., Heberer T. and Linkerhägner M. (1994) Occurrence of clofibric acid in the aquatic system - is the use in human medical care the source of contamination of surface, ground and drinking water? Vom Wass. 83, 57-68.
20. Steger-Hartmann T., Kümmerer K. and Schecker J. (1996) Trace analysis of the antineoplastics IF and cyclophosphamide in sewage water by two step solid phase extraction and GC/MS. J. Chromatogr. A 726, 179-184.
21. Weihs C., Jessenberger J., Kümmerer K. and Steger-Hartmann T. (1995) Prozeß;kontrolle bei einer Simulation-skläranlage. Report Nr. 1/1995. Lehrstuhl Computergestützte Statistik. Fachbereich Statistik, Universität Dortmund.